Myelin Repair Foundation

Mission Statement

To develop rational drug targets to slow, stop and ultimately repair damage to myelin caused by Multiple Sclerosis. We expect to develop candidate treatments within 5 years and work with commercial partners to bring these treatments to market within 15 years. A consortium of scientific and business professionals with all the required competencies will execute a jointly developed research plan and then work with pharmaceutical and biotechnology companies to commercialize viable treatments.